News

Analysis of the Phase 3 explorer7 study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors.

These data highlight the effects on eczema following treatment with dupilumab, tralokinumab, and lebrikizumab in terms of improvements in EASI, IGA, and other measures.

HIIT exercise post-stroke improved aerobic fitness more than MICT, with significant gains in peak VO2 after 12 weeks.

High-risk alcohol use was linked to greater rates of cirrhosis in patients with HCV but did not significantly impact rates of sustained virologic response.

Withdrawal of baricitinib in severe alopecia areata led to hair loss in 80% of patients, highlighting the need for ongoing therapy to maintain regrowth.

These data suggest that physical activity interventions can lead to visible improvements in PASI scores after 20 weeks of implementation, as well as cardiometabolic improvements.

Axatilimab was awarded approval for the treatment of chronic GVHD in adult and pediatric patients who failed ≥2 prior lines of systemic therapy.

Investigators highlight the need for tailored interventions to improve sleep disturbances and overall health in patients with hepatocellular carcinoma.

The accelerated approval is based on phase 3 data demonstrating seladelpar’s impact on ALP reduction and is contingent upon verification and description of clinical benefit in confirmatory trial(s).

A ranibizumab biosimilar lowers costs compared with aflibercept across all nAMD subtypes from both the patient and societal perspectives.

This analysis was conducted to evaluate the effect of pruritus on quality of life ratings among individuals with atopic dermatitis and psoriasis.

Deepak Bhatt, MD, MPH, MBA, discusses 7 trials to watch from hotline or late-breaking sessions at the upcoming European Society of Cardiology Congress 2024.

Noureddin explains the discordance between FIB-4 and transient elastography for stratifying fibrosis risk and emphasizes the importance of repetition and attentiveness with FIB-4.

Preliminary Phase 1b data demonstrated the favorable safety and tolerability profile of VLS-01 buccal film, with psychedelic effects resolved by 120 minutes.

In this analysis, the biggest predictors of biologic initiation among individuals with diagnoses of psoriasis were evaluated.

Findings suggest increased intensity of IgM deposits in patients with positive IgM deposition may contribute to adverse clinicopathologic presentation and clinical outcomes.

New study suggests MRI-derived pressure measurements indicate a 5-fold increase in heart failure risk.

Announced by Rivus Pharmaceuticals, HU6 met its primary endpoint of weight reduction in patients with obesity-related HFpEF in a Phase 2a trial.

Adding vitrectomy with ILM peeling to a treat-and-extend anti-VEGF therapy showed no benefit on visual or anatomic outcomes in DME treatment.

The drug is the first approved monoclonal antibody specifically designed to inhibit the IL-31 pathway, a driver of prurigo nodularis.

This analysis highlights data regarding agreement between various smartphone applications used for detection of melanoma.

Laurence Sperling, MD, provides an overview of the Family Heart Global Summit, including previewing the meeting and discussing where interested attendees can learn more.

Findings highlight a 78.4% treatment success rate among patients who prematurely discontinued DAAs, reaching 93.5% among those who discontinued after week 4.

Ravulizumab therapy may enable patients with PNH to achieve activity and patient-reported outcomes comparable to the US general population.

Maintaining stable HbA1c levels in target ranges reduces Alzheimer Disease risk in older adults with diabetes, emphasizing the importance of personalized glycemic control.

In this interview, Kim speaks about the significance of the FDA approval of neffy for patients who face the threat of anaphylaxis and other severe allergic reactions.

The updated pediatric IgAN prediction tool allows clinicians to assess risk of disease progression 1-2 years post-biopsy.

Cristina Pearse, an MDMA-assisted therapy trial participant, expresses disappointment in the FDA’s decision not to approve MDMA-assisted therapy.